|Nombre||Título||Pagar||Ejecutado||Año de nacimiento|
|Dr. Shankar Musunuri M.B.A., MBA, Ph.D.||Co-Founder, Chairman & CEO||845.2k||6.67M||1964|
|Dr. Uday B. Kompella Ph.D.||Co-founder & Independent Director||44k||N/D||1967|
|Dr. Vijay Tammara Ph.D.||Sr. VP of Regulatory & Quality||490.92k||575.63k||1960|
|Ms. Jessica Crespo CPA, CPA||Chief Accounting Officer, Sr. VP of Fin. and VP of Corp. Controller & Treasurer||N/D||N/D||1977|
|Mr. J. P. Gabriel||Sr. VP of Technical Operations||N/D||N/D||N/D|
|Mr. Ken Inchausti||Head of Investor Relations & Communications||N/D||N/D||N/D|
|Ms. Zara Gaudioso||AVP, Head of HR & Chief of Staff||N/D||N/D||N/D|
|Dr. Arun Upadhyay Ph.D.||Sr. VP of R&D||N/D||N/D||N/D|
|Dr. Bruce D. Forrest B.S., M.B.A., M.D.||Acting Chief Medical Officer & Vaccine Scientific Advisory Board Member||N/D||N/D||1963|
|Mr. Michael Shine||Sr. VP of Commercial||N/D||N/D||N/D|
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
La calificación ISS Governance QuickScore de Ocugen, Inc. a partir del 1 de julio de 2022 es 7. Las puntuaciones principales son Auditoría: 8; Junta: 7; Derechos del accionista: 8; Compensación: 6.